## CB: Chubb Limited - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 2.5% below STRENGTH zone (4.0-10.0%); PEG 2.26 fails VALUE criteria (<1.0); RSI 70 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (38% of avg), overbought RSI (70).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($306.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Lawson Kroeker Investment Management Inc. NE Acquires Shares of 48,521 Chubb Limited $CB**
- Source: MarketBeat | 20251230T125504 | Somewhat-Bullish | Relevance: 100%
- Lawson Kroeker Investment Management Inc. NE has acquired a new position of 48,521 shares in Chubb Limited (NYSE:CB), valued at approximately $13.7 million, making it their 12th largest holding. This comes as several insiders, including EVP Timothy Boroughs and John Lupica, sold significant shares recently, though the company itself beat quarterly earnings expectations and declared a dividend. Analysts currently have a consensus "Hold" rating on Chubb with a target price of $311.90.

**2. Chubb Limited stock edges up as reinsurance renewal report flags lower prices; what CB investors watch next**
- Source: ts2.tech | 20251230T042936 | Somewhat-Bullish | Relevance: 100%
- Chubb Limited (CB) shares rose slightly amid a broader market decline, as a new reinsurance renewal report indicated faster price softening for January 1st renewals. This easing in prices, driven by expanded reinsurance capacity and projected capital growth, benefits insurers like Chubb by lowering their protection costs and influencing future policy pricing. Investors will now monitor upcoming U.S. housing data, Chicago PMI, and the Federal Reserve's meeting minutes for further market direction.

**3. Chubb (CB) Outlook Updated as Morgan Stanley Weighs Pricing and Valuation Trends**
- Source: Finviz | 20251229T210745 | Neutral | Relevance: 100%
- Morgan Stanley analyst Bob Huang updated his outlook for Chubb Limited (NYSE:CB), raising the price target to $310 while maintaining an Equal Weight rating. Despite pressures like softer property pricing and increased competition in personal auto, the insurance sector is seen as attractive due to strong casualty pricing and valuations. Chubb benefits from robust cash generation, a global presence, and reliable income from its investment portfolio, having raised its dividend for 32 consecutive years.

**4. Boston Trust Walden Corp Has $96.64 Million Stake in Chubb Limited $CB**
- Source: MarketBeat | 20251229T102826 | Somewhat-Bullish | Relevance: 100%
- Boston Trust Walden Corp reduced its stake in Chubb Limited (NYSE:CB) by 17.9% in Q3, owning 342,404 shares valued at $96.64 million. Several other institutional investors also adjusted their positions in Chubb, which currently sees 83.81% institutional ownership. The company reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.97 per share.

**5. Medtronic stock slips as year-end trading thins and Fed minutes loom**
- Source: ts2.tech | 20251230T043059 | Neutral | Relevance: 61%
- Medtronic shares closed down 0.4% at $96.15 as year-end trading thins, with investors de-risking and awaiting fresh clues on interest rates from upcoming Federal Reserve minutes. The medical-device maker's decline is attributed to macro positioning rather than company-specific news, though its diabetes business, MiniMed, has filed for an IPO. Investors are also looking ahead to Medtronic's fiscal Q3 2026 earnings report on February 17.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Mizuho | $318 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Mizuho | init | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($14.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-0.3%)
- Berkshire Hathaway, : 7.6% (+15.9%)
- Blackrock Inc.: 6.7% (+0.6%)
- State Street Corpora: 4.1% (+0.4%)
- FMR, LLC: 3.0% (-11.2%)

### Key Risks

1. Heavy insider selling: $15M sold (7 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (10.9x). Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $125.2B |
| Beta | 0.52 |
| 52W Range | $252.16 - $315.08 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 12.0 |
| Current P/E | 13.3 |
| YoY Growth | 11.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 2.5% (minimal 5-day change). Below STRENGTH zone by 1.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 70, risk of mean reversion. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.53% (CS: 83) | Neutral |
| RSI_14 | 70.4 | Overbought |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.100x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $314.15
- **Stop Loss:** $306.47 (2.4% risk)
- **Target:** $321.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $33,614.05
- **Portfolio %:** 33.61%
- **Risk Dollars:** $825.00
- **Risk Per Trade:** 0.83%
- **Modifiers:** L1 110% | L2 75% | Combined 0.83x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-27 (Est: $6.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.16 | $7.49 | +21.7% |
| 2025Q2 | $5.97 | $6.14 | +2.8% |
| 2025Q1 | $3.23 | $3.68 | +14.0% |
| 2024Q4 | $5.45 | $6.02 | +10.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*